Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2022

View Archived Issues

Preprints age well, manuscript preprint shows

New DNA intercalator/topo II inhibitor shows improved anticancer activity over doxorubicin

Prodrug form target of JBP-485 and vitamin E developed to treat NASH

GMQ-3 shows promising efficacy in models of lung cancer

Discovery of novel BU-4664L derivatives with potential anticancer activity

Medshine Discovery patents new GLP-1 receptor agonists

Chinese researchers disclose SOS1 inhibitors

Betta Pharmaceuticals divulges new PTPN11 inhibitors

Roche presents compounds for Gram-negative bacterial infections

Mission Therapeutics synthesizes USP30 inhibitors

Novel halogenated phenoxychalcones described with activity in breast cancer cell lines

Siglec-15 promotes osteosarcoma tumor progression

Inhaled remdesivir shows efficacy in nonhuman primate model of SARS-CoV-2 infection

VC-2 vaccine confers protection against viral ocular immunopathogenesis through T-cell infiltration

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 12, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...